ESMO 2023 – some Tropion fears allayed
However, lack of meaningful efficacy in Tropion-Lung01 suggests that datopotamab deruxtecan might be restricted to a histology-defined NSCLC subgroup.
ESMO 2023 – tarlatamab hits the target for Amgen
But late-breaking data raise questions about lack of a dose response.
ESMO 2023 – Pluvicto’s big splash gets an early preview
Leaked data ahead of the ESMO late breaker show a progression-free survival benefit that looks practice-changing.
Triple meeting 2023 – PRMT5 has a wobble
Initial data on Amgen’s AMG 193 give some Tango investors a headache.
Triple meeting 2023 – Revolution’s KRAS revolution promise draws fans
Phase 1 data suggest the group’s KRAS G12C inhibitor has activity, crucially in KRAS-experienced patients.
Triple meeting 2023 – Relay shifts to a tumour-agnostic plan
The company’s FGFR2 inhibitor shows potential beyond cholangiocarcinoma, but the markets aren’t buying it.
